Study Phase 2

Phase II clinical trial of ET-743 as 2nd or 3rd line treatment in patients with advanced stage and/or metastatic soft tissue sarcoma

  • PDF icon for CSR Summary CSR Summary Not Yet Available
  • Globe symbol for NCT Number NCT Number Not Available
  • Notebook for Primary Citation Primary Citation Not Yet Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameTrabectedinProduct NameYONDELIS®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassAntineoplastic AgentsPharmacological SubgroupPlant Alkaloids and Other Natural ProductsChemical SubgroupOther Plant Alkaloids and Natural ProductsCondition StudiedSarcoma
Sponsor Protocol NumberET-B-010-99EnrollmentN/AData PartnerJohnson & Johnson% FemaleN/AMean/Median Age (Years)N/A% WhiteN/A

Supporting Documentation

  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the annotated CRF, protocol, statistical analysis plan, and full clinical study report are available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.